BioCryst to Report First Quarter 2022 Financial Results on May 5

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) will announce its Q1 2022 financial results on May 5, 2022. A conference call will be held at 8:30 a.m. ET to discuss these results and provide corporate updates. Interested parties can join the call via telephone or access it through a live webcast from the company's investor relations page. BioCryst focuses on developing oral treatments for rare diseases, with products like ORLADEYO approved in multiple countries and ongoing programs for other novel therapies. For more details, visit www.biocryst.com.

RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thursday, May 5, 2022.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 9498023. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 9498023.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals release its Q1 2022 financial results?

BioCryst Pharmaceuticals will release its Q1 2022 financial results on May 5, 2022.

What time is the BioCryst Pharmaceuticals Q1 2022 conference call?

The BioCryst Pharmaceuticals Q1 2022 conference call is scheduled for 8:30 a.m. ET on May 5, 2022.

How can I access the BioCryst Pharmaceuticals conference call?

The call can be accessed by dialing 877-303-8027 for domestic callers or 760-536-5165 for international callers, using conference ID # 9498023.

Where can I find more information about BioCryst Pharmaceuticals?

More information about BioCryst Pharmaceuticals can be found on their official website at www.biocryst.com.

What products does BioCryst Pharmaceuticals currently have on the market?

BioCryst's currently marketed product includes ORLADEYO, an oral treatment for rare diseases, approved in the U.S., EU, Japan, UK, and UAE.